Trials / Withdrawn
WithdrawnNCT01714089
Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis
A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Revalesio Corporation · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether RNS60 is effective in the treatment of RR-MS compared to interferon beta-1a.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RNS60 125 ml | |
| DRUG | RNS60 250 ml | |
| DRUG | Interferon beta 1a |
Timeline
- First posted
- 2012-10-25
- Last updated
- 2016-04-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01714089. Inclusion in this directory is not an endorsement.